Check for updates

CASE REPORT

Case Report: Bocavirus Infection Radiologically Resembling a Congestive Heart Failure in a Patient with Metastatic Castration-Resistant Prostate Cancer Case-Report [version 1; peer review: 1 approved, 1 approved with reservations]

Javier David Benitez Fuentes ^{1,2}, Alicia de Luna Aguilar¹, Paloma Flores Navarro¹, Alfonso Lopez de Sa Lorenzo¹, Carmen Toledano Rojas¹, Berta Laguna Fonseca³, Richa Shah ⁴, Clara Frick⁵, Alejandro Francisco Jimenez Ortega⁶, Natalia Vidal Cassinello¹

¹Departamento de Oncología Médica, San Carlos University Hospital, Madrid, Madrid, 28040, Spain

²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA

³Departamento de Microbiología, San Carlos University Hospital, Madrid, Madrid, 28040, Spain

⁴Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, 69008, France

⁵Public Health, Ludwig Maximilian University of Munich, Munich, Germany

⁶Farmacología Clínica, San Carlos University Hospital, Madrid, Madrid, 28040, Spain

V1 First published: 16 Feb 2022, 11:196
<https://doi.org/10.12688/f1000research.109221.1>
 Latest published: 29 Mar 2022, 11:196
<https://doi.org/10.12688/f1000research.109221.2>

Abstract

Background: Human bocavirus (HBoV) is a viral pathogen from the genus *Bocaparvovirus* (family *Parvoviridae*, subfamily *Parvovirinae*) discovered in 2005. Most of available literature is about HBoV in children and adults with hematological malignancies and in otherwise healthy children with respiratory infections. Information regarding infection in the adult population with solid tumors is scarce.

Case Report: We report the case of a 51-year-old male with metastatic castration resistant prostate cancer undergoing chemotherapy treatment who presented with fever, dyspnea, dry cough, and pleuritic pain. Imaging techniques showed signs of congestive heart failure. Symptoms, laboratory tests and echocardiography revealed a more probable infectious etiology. Antibiotic therapy was started. A polymerase chain reaction (PCR) test of nasopharyngeal exudate for respiratory viruses was positive for HBoV. The rest of the microbiological tests were negative. Bronchoalveolar lavage (BAL) was performed. Bacterial culture of BAL was negative while respiratory virus PCR confirmed positivity for HBoV. Antibiotic therapy was discontinued. The patient gradually recovered.

Conclusions: Emerging infectious diseases are a notorious threat for immunocompromised populations such as solid tumor patients. This

Open Peer Review

Approval Status

	1	2
version 2		
(revision)
29 Mar 2022	view	view

version 1
16 Feb 2022	view	view

1. **Macarena Torrego-Ellacuría** , IdISSC, Madrid, Spain

2. **Marcos Roberto Tovani-Palone** , University of São Paulo, Ribeirão Preto, Brazil

Any reports and responses or comments on the article can be found at the end of the article.

case is unique because to our knowledge this is the first case report article of HBoV in a solid tumor patient and because imaging techniques exhibited signs of congestive heart failure that did not correlate with the rest of the tests. It shows that unusual pathogens should be considered when managing serious clinical complications with uncommon presentations in cancer patients. Notable diagnostic efforts should be made to reach a diagnosis in these cases.

Keywords

Case Report, Bocavirus, Respiratory Tract Infection, Prostate Cancer, Immunocompromised Host, Emerging Communicable diseases

Corresponding author: Javier David Benitez Fuentes (javierdavidbenitezfuentes@gmail.com)

Author roles: **Benitez Fuentes JD:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **de Luna Aguilar A:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Supervision, Validation, Writing – Review & Editing; **Flores Navarro P:** Data Curation, Investigation, Resources; **Lopez de Sa Lorenzo A:** Conceptualization, Data Curation, Writing – Review & Editing; **Toledano Rojas C:** Conceptualization, Data Curation; **Laguna Fonseca B:** Investigation, Writing – Review & Editing; **Shah R:** Writing – Review & Editing; **Frick C:** Writing – Review & Editing; **Jimenez Ortega AF:** Conceptualization, Methodology, Project Administration, Validation, Visualization, Writing – Review & Editing; **Vidal Cassinello N:** Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2022 Benitez Fuentes JD *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Benitez Fuentes JD, de Luna Aguilar A, Flores Navarro P *et al.* **Case Report: Bocavirus Infection Radiologically Resembling a Congestive Heart Failure in a Patient with Metastatic Castration-Resistant Prostate Cancer Case-Report [version 1; peer review: 1 approved, 1 approved with reservations]** F1000Research 2022, 11:196 <https://doi.org/10.12688/f1000research.109221.1>

First published: 16 Feb 2022, 11:196 <https://doi.org/10.12688/f1000research.109221.1>

Introduction

Human bocavirus (HBoV) is a single-stranded DNA viral pathogen belonging to the genus *Bocaparvovirus* (family *Parvoviridae*, subfamily *Parvovirinae*) which comprise four genotypes (HBoV1-4).¹ It was discovered in 2005 by Tobias Allander and coworkers at the Karolinska University Hospital, Stockholm, Sweden in nasopharyngeal aspirates from children with respiratory tract infection (RTI).² It can be found in respiratory secretions in high quantities during the acute phase and it can persist at low viral loads for months.³ Besides respiratory samples, HBoV has been detected in faeces, urine, saliva, blood, tonsils, and cerebrospinal fluid.³ Since its discovery this pathogen has gained recognition as a virus with a wide global distribution. It has an estimated global prevalence of about 6%, depending on the region being studied its prevalence ranges from 1 to 56% of respiratory samples and from 1.3 to 63% of stool samples.³

It is most likely transmitted by air and commonly associated with coinfection with other viruses making it difficult to assert if the main pathogen causing the symptoms is HBoV.⁴ There is evidence that HBoV1 is associated with respiratory disease especially in children.⁵ HBoV1 has also been associated with long periods of persistence in the mucosa of the respiratory tract which might play a role in its frequency of co-infections with other well recognized respiratory pathogens. This concurrent detection of other viral respiratory pathogens is high, some studies show a concurrent detection rate of other viral respiratory pathogens in more than 50% of respiratory specimens.^{4,5}

Most of the articles published focus on HBoV infection in the pediatric population and case reports are usually about immunocompromised pediatric patients, especially pediatric hematopoietic cell transplant recipients and hematologic malignancy pediatric patients.⁵⁻⁸ Some studies have shown that HBoV is an uncommon pathogen in adult patients with severe pneumonia.⁹ In many cases described, in the adult population, in literature HBoV is associated with increased mortality.⁹ HBoV is closely associated with an immunocompromised state and severe comorbidities such as structural lung disease and hematologic malignancy.⁹ Most original articles, case reports and case series published in the immunocompromised adult population show hematopoietic cell transplant recipients and hematologic malignancies as comorbidities with few exceptions. There are few articles regarding the adult population with solid tumors. We found only one study describing the prevalence of HBoV in the adult population with solid tumors from Li *et al*¹⁰ done in Wuhan (China) and published in 2011. This study revealed a prevalence percentage of HBoV infection in adult solid tumor patients of 39.74%.¹⁰ In another study from Lee *et al*¹¹ done in Korea and published in 2019, a total of 185 adult subjects that were diagnosed with HBoV infection between January 2010 and December 2017 and were enrolled into the study. From these 185, 28 had solid tumors.¹¹ Their clinical characteristics and risk factors for pneumonia were retrospectively evaluated.

In this case report we examine the case of a 59-year-old patient with a history of metastatic castration-resistant prostate cancer suffering from HBoV infection. To our knowledge this is the first case report article of a solid tumor patient infected with HBoV.

Case report

We report the case of a 59-year-old Caucasian male barbershop owner, former smoker, diagnosed with achalasia in January 2019 treated with Heller myotomy and Toupet fundoplication on the 6th of May 2021. In November 2019 he complained of bone pain at different anatomic locations and was diagnosed with metastatic prostate cancer and bone only disease.

The patient was started on androgen deprivation therapy, immunotherapy with ipilimumab and nivolumab as well as chemotherapy with docetaxel in December 2019 as part of a clinical trial (NCT03879122). He initially received two cycles of intravenous ipilimumab 3 milligrams/kilogram (mg/kg) with intravenous nivolumab 3 mg/kg once a day on day one every three weeks for 6 weeks. Ipilimumab was discontinued due to grade three diarrhea, which was treated with a course of high dose oral steroids (equivalent to 2 mg/kg of prednisone) for two weeks until complete recovery. He then received four cycles of intravenous docetaxel 75 milligrams/square meter of body surface area (mg/m²) with intravenous nivolumab (3 milligrams/kilogram) once a day on day one every three weeks for twelve weeks, followed by maintenance with intravenous nivolumab at the same dose and schedule as part of the study protocol. The treatment continued unchanged until November 2020 when it was stopped due to bone and serologic progression. After November 2020 the patient was started on abiraterone (1000 mg once a day) plus 5 milligrams of prednisone twice a day and received radiotherapy over the bone metastases in progression. In May 2021 treatment was changed due to serologic and bone progression to intravenous cabazitaxel (20 mg/m²) once a day every three weeks plus prednisone 5mg twice a day every day. Dexamethasone 4 mg once a day everyday was added at the beginning of June 2021 due to bone pain.

On the 26th of June 2021, the patient arrived at the emergency department complaining of fever at home, dyspnea, dry cough, and left side pleuritic chest pain for the last seven days. The sequence of events is detailed in the timeline (Figure 1). Oral levofloxacin (500 mg) every 24 hours was started one week before the arrival of the patient to the

Figure 1. Timeline of events.

emergency department with no improvement. His blood pressure was 90/50 mmHg (hypotension defined by 90/60 mmHg or below), temperature was 36.8°C (normal temperature level is between 36.1°C and 37.2°C), heart rate was 95 bpm (normal heart rate for adults 60 to 100 beats per minute), respiratory rate was 24 bpm (normal respiratory rate for adults 12 to 16 breaths per minute), peripheral oxygen saturation was 88% (normal level equal or more than 95%) with no supplemental oxygen.

Physical exam was pertinent with generalized decreased breath sounds with no signs of peripheral edema.

Laboratory tests with complete blood count, coagulation panel, comprehensive metabolic panel, liver function tests, renal function tests and acute phase reactants revealed hemoglobin level of 8 grams/deciliter (normal level for males, 13.5 to 17.5 grams/deciliter), C-Reactive Protein (CRP) of 47.9 milligrams/liter (normal level less than 10 milligrams/liter),

procalcitonin of 0.14 nanograms/milliliter (normal level less than 0.1 nanograms/milliliter), sodium of 127 milliequivalents/liter (between 135 and 145 milliequivalents/liter), lactate of 0.8 millimoles/liter (Normal lactate range is less than 2.3 millimoles/liter), the rest of the complete blood count, coagulation panel, comprehensive metabolic panel, liver function tests and renal function tests were normal (Figure 2). Arterial blood gases showed a partial pressure of oxygen of 57 mmHg and a partial pressure of carbon dioxide of 27 mmHg.

Cardiac enzymes and N-terminal pro-brain natriuretic peptide (NT-proBNP) were negative. An electrocardiogram showed no remarkable alterations. A chest radiograph (Figure 3) exhibited an enlarged cardiac silhouette. A computed tomography angiogram of the chest was performed to confirm or rule out the possibility of a pulmonary embolism. It showed no signs of pulmonary embolism but confirmed an enlarged cardiac silhouette and exhibited a mild bilateral pleural effusion. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR), influenza PCR and *Streptococcus pneumoniae* and *Legionella pneumophila* urinary antigen tests all came back negative. Finally, blood, urine and sputum samples were collected for culture.

Based on the respiratory and heart rate, hypotension, CRP elevation and fever, a serious infection could not be ruled out. Having a negative NT-proBNP did not point to a congestive failure despite imaging techniques.^{12,13} Wide spectrum antibiotics with intravenous meropenem (2 grams/8 hours), oral linezolid (600 milligrams/12 hours) and intravenous

2021-06-26	<ul style="list-style-type: none"> • Procalcitonin 0.14 nanograms/milliliter • Lactate dehydrogenase 495 units/liter • NT-proBNP 350 picograms/milliliter • CRP 47.9 milligrams/liter • Neutrophils 4310 cells/μL
2021-07-05	<ul style="list-style-type: none"> • Procalcitonin 0.04 nanograms/milliliter • Lactate dehydrogenase 440 units/liter • CRP 22.3 milligrams/deciliter • Neutrophils 3900 cells/microliter

Figure 2. Diagnostic tests at admission and discharge. N-terminal pro-brain natriuretic peptide (NT-proBNP), C-Reactive Protein (CRP).

Figure 3. Chest radiograph at hospital admission.

Figure 4. Chest radiograph at hospital discharge.

trimethoprim/sulfamethoxazole (320/1600 milligrams/6 hours) as well as intravenous fluid therapy, and symptomatic treatment were started following hospital protocols. Oral dexamethasone previously prescribed for bone pain was increased to 4 mg twice a day as part of the treatment of acute respiratory insufficiency. The patient was transferred to the medical oncology inpatient ward.

During his stay an echocardiogram was performed revealing a normal size left ventricle, with no segmentary alterations and a left ventricular ejection fraction within normal values.

Blood, urine, and sputum cultures were negative for bacterial and fungal pathogens. The medical team then requested a respiratory viruses PCR in nasopharyngeal exudate that displayed positivity for HBoV. The other viruses tested for (Influenza A, Influenza B, Influenza C, Parainfluenza 1, Parainfluenza 2, Parainfluenza 3, Parainfluenza 4, Enterovirus B, Rhinovirus, Coronavirus 229, Adenovirus, Metapneumovirus A, Metapneumovirus B, Respiratory syncytial virus A, Respiratory syncytial virus B) were negative. Based on the common concurrent infection rates with other pathogens bronchoscopy was performed and bronchoalveolar lavage (BAL) was done to collect samples. Culture and a respiratory virus PCR were performed in BAL. The culture was negative for bacteria and fungi. The PCR was again, positive for HBoV. Antibiotic therapy was discontinued based on these results and progressive clinical and analytical improvement was shown with gradual decrease in acute phase reactants.

The patient gradually recovered from the dyspnea, chest pain and dry cough having no more episodes of fever during hospitalization. A second chest radiograph (Figure 4) before discharge shows a normal size cardiac silhouette while maintaining the mild bilateral pleural effusion. After eight days from hospital admission the patient was discharged home. He was re-evaluated two weeks after discharge in medical oncology outpatient clinic reporting no further complications with normal laboratory tests with complete blood count, comprehensive metabolic panel, and acute phase reactants.

Patient perspective

I usually never complain but this time the pain and lack of breath were unbearable I could not keep waiting for these symptoms to go away. The first days I spent at the hospital I had lots of diagnostics tests done before the medical team could reach a diagnosis but at least they were done fast. During the time at the hospital started to feel better slowly but in the end, I could completely recover.

Discussion

We report an infection with an emerging pathogen in a solid tumor patient. The case is rare as it presented contradictory diagnostic test results with an uncommon radiological image.

Emerging viral pathogens represent a growing threat for all people but especially for immunocompromised populations. Ultimately, we have seen an extremely prevalent example of this problem with the SARS-CoV-2. The coronavirus disease 2019 (COVID-19) pandemic takes a bigger mortality and morbidity toll when affecting cancer patients.¹⁴

HBoV was first described in 2005,² however we do not have much information about its prevalence in patients suffering from solid neoplasms. With the one exception being the study from Li *et al*¹⁰ that shows an almost 40% (62/156) HBoV prevalence among solid tumor patients compared to 3.51% (33/941) in children with respiratory tract infections. However, this study only reflects the population from Wuhan, and it does not have any clinical information regarding the patients enrolled. Meaning this data is likely to be different globally.

In a study by Lee *et al*¹¹ 185 patients infected with HBoV were enrolled. From the 185 patients, 76 (41.08%) were immunocompromised. From the immunocompromised patients 28 (36.84%) suffered solid malignancies treated with chemotherapy within 6 months of HBoV diagnosis, 11 (14.47%) had hematologic malignancies, 19 (25%) had solid organ transplantations, and 18 (23.68%) received hematopoietic cell transplantation. Of the 185, 110 had pneumonia. CT findings were analyzed in 34 of the 185 patients, from which 16 were immunocompromised. There was no significant difference in CT patterns between immunocompetent and immunocompromised patients and the most frequent findings in both groups were bilateral consolidation and/or ground glass opacities. Pleural effusion was observed in 50.0% patients.

In our case report the patient presented with laboratory tests that pointed to an acute infectious process with a potential respiratory origin, however imaging techniques showed conflicting data revealing an enlargement of the cardiac silhouette indicating a possible congestive heart failure. Vital signs, physical examination, a normal echocardiogram, clinical judgment, and the clinical picture all together tipped the balance towards an infectious diagnosis.

After the negative results in the sputum, urine and blood culture, a PCR in nasopharyngeal exudate was performed, presenting a positive result for HBoV. Thus, revealing the probable cause of the patient's current pathologic process. Based on the fact that it is very common to have coinfections with other viruses HBoV had to be confirmed in BAL which revealed no other pathogen.⁵ This finding was concordant with the bilateral pleural effusion based on available published articles¹¹ but not with the cardiac silhouette enlargement. After clinical improvement was noted a new chest radiography was performed that did not display an enlarged cardiac silhouette.

To our knowledge this is the first case report article of a solid tumor patient infected with HBoV. The discordant imaging and laboratory tests show the need for a clinical judgement that considers all aspects of the clinical picture and reinforces the necessity of further diagnostic efforts when diagnostic test results are conflicting. This is especially true in immunocompromised populations at risk of serious complications in case of a delayed diagnosis and treatment.

Data availability

All data associated with this article are available in the paper and no additional source data is required.

Consent

Written informed consent for publication of their clinical details, clinical images, and views on the treatment was obtained from the patient.

References

1. Lüsebrink J, Wittleben F, Schildgen V, *et al.*: **Human bocavirus - insights into a newly identified respiratory virus.** *Viruses*. 2009 Jun; **1**(1): 3–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Allander T, Tammi MT, Eriksson M, *et al.*: **Cloning of a human parvovirus by molecular screening of respiratory tract samples.** *Proc. Natl. Acad. Sci. U. S. A.* 2005 Sep 6; **102**(36): 12891–12896. Epub 2005 Aug 23. Erratum in: *Proc Natl Acad Sci U S A.* 2005 Oct 25; **102**(43):15712.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Polo D, Lema A, Gándara E, *et al.*: **Prevalence of human bocavirus infections in Europe. A systematic review and meta-analysis.** *Transbound. Emerg. Dis.* 2021 Jul 12. Epub ahead of print.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Jiang W, Yin F, Zhou W, *et al.*: **Clinical significance of different virus load of human bocavirus in patients with lower respiratory tract infection.** *Sci. Rep.* 2016 Feb; **6**(6): 20246.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Christensen A, Nordbø SA, Krokstad S, *et al.*: **Human bocavirus in children: mono-detection, high viral load and viraemia are associated with respiratory tract infection.** *J. Clin. Virol.* 2010 Nov; **49**(3): 158–162.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

6. Han SB, Shin JA, Kim SK, *et al.*: **Respiratory Viral Infections in Children and Adolescents with Hematological Malignancies.** *Mediterr J. Hematol. Infect. Dis.* 2019 Jan 1; **11**(1): e2019006.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Pochon C, Voigt S: **Respiratory Virus Infections in Hematopoietic Cell Transplant Recipients.** *Front. Microbiol.* 2019 Jan; **9**(9): 3294.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Schenk T, Strahm B, Kontny U, *et al.*: **Disseminated bocavirus infection after stem cell transplant.** *Emerg. Infect. Dis.* 2007 Sep; **13**(9): 1425–1427.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Choi SH, Huh JW, Hong SB, *et al.*: **Severe Human Bocavirus-Associated Pneumonia in Adults at a Referral Hospital, Seoul, South Korea.** *Emerg. Infect. Dis.* 2021 Jan; **27**(1): 226–228.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Li Y, Dong Y, Jiang J, *et al.*: **High prevalence of human parvovirus infection in patients with malignant tumors.** *Oncol. Lett.* 2012 Mar; **3**(3): 635–640.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Lee HN, Koo HJ, Kim SH, *et al.*: **Human Bocavirus Infection in Adults: Clinical Features and Radiological Findings.** *Korean J. Radiol.* 2019 Jul; **20**(7): 1226–1235.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Singer M, Deutschman CS, Seymour CW, *et al.*: **The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).** *JAMA.* 2016 Feb 23; **315**(8): 801–810.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Ponikowski P, Voors AA, Anker SD, *et al.*: **2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.** *Eur. J. Heart Fail.* 2016 Aug; **18**(8): 891–975.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Yarza R, Bover M, Paredes D, *et al.*: **SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death.** *Eur. J. Cancer.* 2020 Aug; **135**: 242–250.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 17 March 2022

<https://doi.org/10.5256/f1000research.120698.r123948>

© 2022 Tovani-Palone M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Marcos Roberto Tovani-Palone

Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil

This is an interesting article that describes and discusses the case of a 59-year-old patient with a history of metastatic castration-resistant prostate cancer suffering from HBV infection.

The article is well structured, with a complete description of the case and relevant discussion. Furthermore, the references used are up to date and appropriate and the figures are very illustrative.

However, revisions are required to refine the article. Authors should reread the article in an attempt to review it for grammatical mistakes and writing style.

Is the background of the case's history and progression described in sufficient detail?

Yes

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?

Yes

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?

Yes

Is the case presented with sufficient detail to be useful for other practitioners?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Pathology, General medicine, Dentistry, Global and Public health

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 20 Mar 2022

Javier David Benitez Fuentes

Article has been reread by various author correcting minor mistakes and improving writing style. We have also added one image from the computed tomography angiogram of the chest to increase the visual aspect of the case.

Competing Interests: No competing interests

Reviewer Report 09 March 2022

<https://doi.org/10.5256/f1000research.120698.r125565>

© 2022 Torrego-Ellacuría M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Macarena Torrego-Ellacuría

Department of Endocrinology and Nutrition, Hospital Clínico San Carlos, IdISSC, Madrid, Spain

Interesting, detailed, and justified article. Some minor suggestions to improve:

1. Introduction, third paragraph, line 1: change "*articles published*" for "*published articles*" (structure adjective + noun).
2. Introduction, third paragraph, penultimate line. Replace "*From these 185*" with "*Of these 185, 28 (15,13%) had solid tumours*".
3. Use the International System of Units (SI) symbols for the expression of all dose or concentrations related to biological samples, always leaving a space between the figure and the symbol used (pages 3,4,5, and figure 2). For the pharmacological treatment regimen (e.g. 2 grams every 8 hours or 600 milligrams every 8 hours) the current expression can be retained, without abbreviations.
4. Figure 1: include figure legend with abbreviations used in the figure.

Is the background of the case's history and progression described in sufficient detail?

Yes

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?

Yes

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?

Yes

Is the case presented with sufficient detail to be useful for other practitioners?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Pharmacy, clinical research

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 19 Mar 2022

Javier David Benitez Fuentes

From your suggestions, I have followed points 1, 2, 4. Point 3 was done this way based on the comments from the editors of the journal so I will keep them that way. Thank you

Competing Interests: No competing interests.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research